Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 33,125 shares at $41.53 ($1.4M) on 2025-01-08, disclosed to the SEC on 2025-01-10.
Scheduled sale ($1.4M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.53 | 9,975 | $414K | 30.0% |
| 2 | $41.53 | 9,975 | $414K | 30.0% |
| 3 | $42.00 | 1,875 | $79K | 5.7% |
| 4 | $42.03 | 5,650 | $237K | 17.2% |
| 5 | $42.03 | 5,650 | $237K | 17.2% |
| Total | $41.73 avg | 33,125 |
| $1.4M |
| 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |